Mallinckrodt Completes Divestiture of Therakos® Business
Portfolio Pulse from
Mallinckrodt has completed the sale of its Therakos business to CVC Capital Partners for $925 million, significantly reducing its net debt by over 60%. This move aligns with the company's strategy to optimize its capital structure.
December 02, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mallinckrodt has sold its Therakos business for $925 million, reducing its net debt by more than 60%. This divestiture is part of the company's strategy to optimize its capital structure.
The sale of Therakos for $925 million allows Mallinckrodt to significantly reduce its net debt by over 60%, which is a substantial improvement in its financial health. This aligns with the company's strategic priorities and is likely to be viewed positively by investors, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100